Can a DaT (Dopamine Transporter) scan help diagnose Progressive Supranuclear Palsy (PSP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

A DAT scan can be a valuable tool in helping to diagnose Progressive Supranuclear Palsy (PSP) by demonstrating abnormal patterns of dopaminergic depletion. The DAT scan works by using a radioactive tracer, such as I-123 ioflupane, which binds to dopamine transporters, allowing for the visualization of dopamine activity in the brain 1. This can help differentiate PSP from conditions that do not affect the dopaminergic system, such as essential tremor or drug-induced parkinsonism.

Key Points to Consider

  • A normal I-123 ioflupane SPECT/CT essentially excludes Parkinsonian syndromes, including PSP 1.
  • The DAT scan can demonstrate decreased radiotracer uptake in the striatum, usually in a posterior to anterior direction from the putamen to the caudate nuclei, which is indicative of dopaminergic depletion 1.
  • While a DAT scan cannot definitively diagnose PSP on its own, it can be used in conjunction with clinical evaluation and other imaging studies, such as MRI, to reach an accurate diagnosis 1.

Clinical Application

In clinical practice, a DAT scan can be a useful adjunct to clinical evaluation in diagnosing PSP, particularly in differentiating it from other parkinsonian syndromes and non-parkinsonian conditions. However, it is essential to interpret the DAT scan results alongside the patient's symptoms, neurological examination findings, and possibly other imaging studies to reach an accurate diagnosis of PSP.

From the Research

DAT Scan and PSP Diagnosis

  • A DAT scan can be helpful in diagnosing Progressive Supranuclear Palsy (PSP) by assessing the integrity of presynaptic dopamine transporters in the striatum 2, 3, 4, 5.
  • Studies have shown that DAT scan can distinguish between PSP and other parkinsonian syndromes, such as Parkinson's disease (PD) and multiple system atrophy (MSA) 4, 5.
  • The putamen-to-caudate nucleus ratios on DAT scan can be significantly different between PD and PSP patients, which can aid in diagnosis 2, 5.
  • DAT scan can also identify dopamine receptor dysfunction early in the disease course in progressive apraxia of speech, a neurodegenerative syndrome that can predictably develop into PSP 3.

Comparison with Other Imaging Modalities

  • Fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging can also be used to analyze the characteristics of cerebral glucose metabolism in PSP patients, which can aid in diagnosis 6.
  • Magnetic resonance imaging (MRI) features, such as the "hummingbird" sign, can also be helpful in diagnosing PSP 6.
  • However, DAT scan has been shown to be a sensitive and accurate measure of dopamine degeneration, which can be useful in distinguishing PSP from other parkinsonian syndromes 2, 4, 5.

Limitations and Future Studies

  • More studies are needed to fully understand the role of DAT scan in diagnosing PSP and to determine its sensitivity and specificity in differentiating PSP from other parkinsonian syndromes 2, 3, 4, 5.
  • Further research is also needed to explore the potential of DAT scan in monitoring disease progression and response to treatment in PSP patients 2, 3, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.